AP2024A - Microbicidal pyrimidine or triazine for preventingsexual HIV transmission - Google Patents

Microbicidal pyrimidine or triazine for preventingsexual HIV transmission

Info

Publication number
AP2024A
AP2024A AP2004003182A AP2004003182A AP2024A AP 2024 A AP2024 A AP 2024A AP 2004003182 A AP2004003182 A AP 2004003182A AP 2004003182 A AP2004003182 A AP 2004003182A AP 2024 A AP2024 A AP 2024A
Authority
AP
ARIPO
Prior art keywords
preventingsexual
triazine
hiv transmission
microbicidal
pyrimidine
Prior art date
Application number
AP2004003182A
Other languages
English (en)
Other versions
AP2004003182A0 (en
Inventor
Roey Jens Marcel Van
M M G De Bethune Marie-Pierre T
Paul Stoffels
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of AP2004003182A0 publication Critical patent/AP2004003182A0/xx
Application granted granted Critical
Publication of AP2024A publication Critical patent/AP2024A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AP2004003182A 2002-05-13 2003-05-13 Microbicidal pyrimidine or triazine for preventingsexual HIV transmission AP2024A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076897 2002-05-13
PCT/EP2003/050158 WO2003094920A1 (en) 2002-05-13 2003-05-13 Microbicidal pyrimidine or triazine for preventing sexual hiv transmission

Publications (2)

Publication Number Publication Date
AP2004003182A0 AP2004003182A0 (en) 2004-12-31
AP2024A true AP2024A (en) 2009-08-11

Family

ID=29414777

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2004003182A AP2024A (en) 2002-05-13 2003-05-13 Microbicidal pyrimidine or triazine for preventingsexual HIV transmission

Country Status (27)

Country Link
US (4) US7935710B2 (zh)
EP (1) EP1505980B1 (zh)
JP (2) JP4530848B2 (zh)
KR (1) KR101095358B1 (zh)
CN (2) CN1668305B (zh)
AP (1) AP2024A (zh)
AR (1) AR039540A1 (zh)
AT (1) ATE376420T1 (zh)
AU (1) AU2003240844B2 (zh)
BR (2) BRPI0310021B8 (zh)
CA (1) CA2486078C (zh)
CY (1) CY1110249T1 (zh)
DE (1) DE60317060T2 (zh)
DK (1) DK1505980T3 (zh)
EA (1) EA011298B1 (zh)
ES (1) ES2294291T3 (zh)
HK (1) HK1173141A1 (zh)
HR (1) HRP20041177B1 (zh)
IL (1) IL165174A (zh)
MX (1) MXPA04011392A (zh)
NO (2) NO331030B1 (zh)
NZ (1) NZ536976A (zh)
PL (1) PL215128B1 (zh)
PT (1) PT1505980E (zh)
SI (1) SI1505980T1 (zh)
WO (1) WO2003094920A1 (zh)
ZA (1) ZA200409984B (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
CN102151270A (zh) 2003-02-07 2011-08-17 詹森药业有限公司 预防hiv感染的嘧啶衍生物
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
ITMI20031640A1 (it) 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
BRPI0607811B8 (pt) * 2005-02-18 2021-05-25 Janssen R & D Ireland derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmos, processo para preparar a referida composição e uso
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007071199A1 (fr) * 2005-12-22 2007-06-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Composes de 2,4-disubstituee amido-6-substituee-[1,3,5]triazine ou de 1,3-pyrimidine, leurs procedes d'elaboration, et preparations pharmaceutiques les contenant et leurs utilisations
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
RU2008152195A (ru) 2006-06-15 2010-07-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа
AU2007257701A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
BRPI0722383A2 (pt) 2006-12-08 2012-06-05 Irm Llc compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos
ES2550152T3 (es) * 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
US9006243B2 (en) * 2006-12-29 2015-04-14 Janssen R&D Ireland HIV inhibiting 6-substituted pyrimidines
ES2618057T3 (es) * 2006-12-29 2017-06-20 Janssen Sciences Ireland Uc Pirimidinas 5,6-sustituidas inhibidoras del VIH
CA2702674C (en) 2007-10-19 2016-05-03 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
DK2576541T3 (en) 2010-06-04 2016-05-30 Hoffmann La Roche Aminopyrimidine AS LRRK2 MODULATORS
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
LT3124483T (lt) 2010-11-10 2019-09-25 Genentech, Inc. Pirazolo aminopirimidino dariniai, kaip lrrk2 moduliatoriai
US10426761B2 (en) 2011-04-19 2019-10-01 Arms Pharmaceutical, Llc Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US20130039959A1 (en) * 2011-04-19 2013-02-14 Brian Vincent Sokol Method of inhibiting hiv and barrier-forming composition therefor
CN103619341A (zh) 2011-04-19 2014-03-05 Arms制药有限公司 抑制有害微生物的方法及其阻隔形成组合物
MX360404B (es) 2011-05-04 2018-10-31 Ariad Pharma Inc Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN102675212B (zh) * 2012-05-09 2014-11-05 昆明理工大学 N-取代苯基-2-((1h-苯并咪唑-2-基)巯基)乙酰胺类衍生物及其用途
CA2891412A1 (en) 2012-11-20 2014-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
JP6466107B2 (ja) * 2014-09-04 2019-02-06 東ソー・ファインケム株式会社 ４−フェニルチオ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105085410B (zh) * 2015-08-21 2017-10-10 武汉工程大学 一种二芳基嘧啶类hiv‑1抑制剂及其制备方法
WO2017077520A1 (en) 2015-11-06 2017-05-11 Ineb - Instituto Nacional De Engenharia Biomédica A composition for use in a method for prevention or treatment of human immunodeficiency virus infections
CN106478521A (zh) * 2016-10-11 2017-03-08 武汉工程大学 一种二芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法
CN106866628A (zh) * 2017-02-27 2017-06-20 武汉工程大学 一种芳基杂芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法
CA3060416A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
CN109053613A (zh) * 2018-07-04 2018-12-21 复旦大学 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途
MX2021003723A (es) * 2018-12-04 2021-05-13 Virox Tech Inc Composiciones antimicrobianas que contienen n-alquil gamma butirolactama de c3-c5 y usos de las mismas.
US20220033851A1 (en) * 2020-08-03 2022-02-03 Roger B. Swartz mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A.
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
WO2023220645A1 (en) 2022-05-10 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccine for human t-lymphotropic virus-1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050250A1 (en) * 1998-03-27 1999-10-07 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidine derivatives
WO1999050256A1 (en) * 1998-03-27 1999-10-07 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
WO2000027828A2 (en) * 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. 2,4-disubstituted triazine derivatives with anti hiv activity
WO2000027825A1 (en) * 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983393A (en) * 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
IT1229531B (it) 1988-01-20 1991-09-04 Univ Minnesota Composti nucleosidi dideossidideidrocarbociclici e formulazione farmaceutica che li contiene
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JPH075570B2 (ja) 1990-03-29 1995-01-25 三菱化学株式会社 ピリミジンヌクレオシド誘導体及び該誘導体を有効成分とする抗ウイルス剤
DK0539442T3 (da) 1990-07-19 1998-09-07 Wellcome Found Enzyminaktivatorer
GB9214720D0 (en) * 1992-07-10 1992-08-19 Wellcome Found Enzyme inhibitors
DE69414708T2 (de) * 1993-08-24 1999-04-15 Medivir Ab, Huddinge Verbindungen und methoden zur inhibition von hiv und verwandten viren
US6165493A (en) 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
PL351710A1 (en) * 1999-05-14 2003-06-02 Univ California Anti−inflammatory therapy for inflammatory mediated infection
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
ATE316781T1 (de) 1999-09-24 2006-02-15 Janssen Pharmaceutica Nv Antivirale feste dispersionen
US20030165540A1 (en) 2000-05-05 2003-09-04 Jen-Kuei Liu Sentinel virus II
US7034019B2 (en) * 2000-05-08 2006-04-25 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
WO2001085700A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CA2439820A1 (en) * 2001-03-02 2002-09-12 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
US6951654B2 (en) 2001-03-27 2005-10-04 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050250A1 (en) * 1998-03-27 1999-10-07 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidine derivatives
WO1999050256A1 (en) * 1998-03-27 1999-10-07 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
WO2000027828A2 (en) * 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. 2,4-disubstituted triazine derivatives with anti hiv activity
WO2000027825A1 (en) * 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines

Also Published As

Publication number Publication date
DE60317060D1 (de) 2007-12-06
SI1505980T1 (sl) 2008-02-29
CN102558070B (zh) 2016-01-13
JP4530848B2 (ja) 2010-08-25
CY1110249T1 (el) 2015-01-14
KR20050010798A (ko) 2005-01-28
NZ536976A (en) 2007-08-31
BR122014006936B1 (pt) 2020-11-24
CN1668305A (zh) 2005-09-14
BR122014006936B8 (pt) 2021-05-25
AR039540A1 (es) 2005-02-23
MXPA04011392A (es) 2005-02-17
IL165174A (en) 2011-01-31
AP2004003182A0 (en) 2004-12-31
EA200401494A1 (ru) 2005-06-30
EA011298B1 (ru) 2009-02-27
JP5256244B2 (ja) 2013-08-07
PL215128B1 (pl) 2013-10-31
ZA200409984B (en) 2006-07-26
BR0310021A (pt) 2005-02-15
PT1505980E (pt) 2008-01-17
NO334067B1 (no) 2013-12-02
NO20110298L (no) 2005-02-14
NO331030B1 (no) 2011-09-19
ATE376420T1 (de) 2007-11-15
BRPI0310021B8 (pt) 2021-05-25
JP2010189435A (ja) 2010-09-02
NO20045267L (no) 2005-02-14
BRPI0310021B1 (pt) 2018-03-13
CA2486078C (en) 2011-08-23
US7935710B2 (en) 2011-05-03
US20110165093A1 (en) 2011-07-07
AU2003240844B2 (en) 2008-09-11
US20170100399A1 (en) 2017-04-13
DE60317060T2 (de) 2008-07-24
US20200345733A1 (en) 2020-11-05
AU2003240844A1 (en) 2003-11-11
IL165174A0 (en) 2005-12-18
US20060166943A1 (en) 2006-07-27
ES2294291T3 (es) 2008-04-01
EP1505980A1 (en) 2005-02-16
KR101095358B1 (ko) 2011-12-16
HK1173141A1 (zh) 2013-05-10
CN1668305B (zh) 2013-06-12
WO2003094920A1 (en) 2003-11-20
HRP20041177A2 (hr) 2006-04-30
PL373840A1 (en) 2005-09-19
DK1505980T3 (da) 2008-02-11
CN102558070A (zh) 2012-07-11
CA2486078A1 (en) 2003-11-20
JP2005526846A (ja) 2005-09-08
HRP20041177B1 (hr) 2013-03-31
EP1505980B1 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
AP2024A (en) Microbicidal pyrimidine or triazine for preventingsexual HIV transmission
HUS2200038I1 (hu) HIV-gátló pirimidinszármazékok
EG24843A (en) Herbicidal pyrimidines
EP1546115A4 (en) SUBSTITUTED PYRIMIDINES
AP2005003403A0 (en) Substituted pyrimidinones.
MXPA03007166A (es) Pirido-pirimidinas 6-sustituidas.
AP2005003366A0 (en) Pyrimidine derivatives for the prevention of HIV infection.
IL162189A0 (en) Pyrimidine compounds
HK1070071A1 (en) New pyrimidine compounds
MXPA03007433A (es) Pirazolil pirimidinas.
GB0112802D0 (en) Pyrimidine derivatives
AU2003230809A8 (en) Antimicrobial surfaces
GB0112803D0 (en) Pyrimidine derivatives
GB0119477D0 (en) Pyrimidine derivatives
TWI315199B (en) Hiv replication inhibiting pyrimidines
GB0112807D0 (en) Pyrimidine derivatives
GB0112804D0 (en) Pyrimidine derivatives
GB0112805D0 (en) Pyrimidine derivatives
GB0119475D0 (en) Pyrimidine derivatives
GB0112809D0 (en) Pyrimidine derivatives
GB0112808D0 (en) Pyrimidine derivatives
SI1567522T1 (sl) Pirimidinske spojine
AU2002338904A1 (en) Substituted pyrimidines
SI1361880T1 (sl) 6-substituirani pirido-pirimidini
GB0219304D0 (en) Pyrimidine derivatives